Currently, the field of radiation therapy is changing in terms of radiation type, and there are several changes in adoption patterns among its end-user segments. The end users are shifting from conventional radiation (Xray, or Cobalt-60, among others) to modern radiation such as a proton or heavy ion radiation. The increasing demand for modern radiation therapy systems has led to the increasing awareness of cancer/tumor treatments. The primary role of these systems is to shrink or destroy cancer/tumor depending on cancer/tumor type, stage, patient age, number of radiation sessions required, and many other factors. Radiation therapy can be divided primarily into external beam radiation therapy, also known as teletherapy, and internal beam radiation therapy, also known as brachytherapy. In the past decade, the definition of these technologies has expanded. Earlier the radiation therapy was only referred to as a simple therapy only done by the radiation beam. Now, radiation therapy includes internal radiation or external radiation combined with chemotherapy or open body surgery or combining various radiation therapy techniques such as IGRT, VMAT, and SRS to destroy or shrink cancer/ tumor. The ongoing trend of offering new radiation therapy systems which have proton or heavy ion beam, integration of two different radiation therapies, and integration of imaging technology with radiation therapy systems showcase the growing future of technological innovations and advancements in radiation therapy in the oncology field.

Practically overnight, clinicians, healthcare providers, pharmaceutical companies and payers shifted much of their work onto virtual platforms and other digital technologies. As consumers grappled with a deadly new virus, providers embraced virtual technology in unprecedented numbers so they could continue to serve patients despite restrictions on in-person interactions. In doing so, they packed a decade’s worth of reforms into a few short months. Players across the industry boosted data analytics capabilities to respond to ongoing shifts in healthcare needs, consumer behaviour and the economy. The deployment of digital tools in clinical trials helped companies quickly test whether existing medicines worked against the new virus and enabled the rapid development of COVID-19 vaccines. And work began to shore up the weaknesses evident in the healthcare supply chain. All this took place amid the broader backdrop of changes coursing through the industry and a set of long-standing common issues affecting the health ecosystem. In the years before the pandemic, and in the months since COVID-19 altered the course of history, a series of transformations has been altering traditional paradigms. And they will continue to do so in coming years. These include a heightened focus on well-being and prevention, the push to develop cures in addition to treatments, paying based on outcomes rather than fee-for-service, new developments in gene therapy and precision medicine, cross-industry convergence, and an end-to-end focus on patient and clinician experience. These themes intersect and interact with significant issues, including excessive cost; health inequities; inadequate transparency, interoperability and collaboration; and a general lack of trust.

The global surgical instrument tracking devices market is expected to grow at a CAGR of 9.16% for the forecast period 2021-2031. Leading market players strive to retain a competitive edge by having a good presence in key markets and offering a diverse product range. The market has witnessed a total of 32 key developments over the five years (January 2016-March 2021), with a majority of them being product offerings and upgradation accompanied by partnerships, alliances, and business expansions. Efforts are being made to bring more technologically innovative goods to market, each aimed at a particular unmet need. With the launch of new and updated devices with improved features, surgical instrument tracking devices technology has become increasingly possible to unlock new use cases.

Direct-to-consumer genetic tests (DTC-GT) offers its consumers the ability to solve their individual genetic puzzle. The confluence of breakthroughs in genetic testing has not only decreased the time required to perform a genetic test but also has reduced the cost of conducting these tests. All these factors combined have given DTC-GT a lot of acceptance among the consumers. The major proponent of the DTC-GT market is the distribution channels opted by the companies. The companies are marketing these tests via online or retail channels. With the piqued advertisements of these tests through print, media, and the internet, the industry is gaining familiarity among consumers. Companies such as 23andme, Mapmygenome, Ancestry.com, EasyDNA, and 24Genetic are offering a large number of diversified services related to genealogy testing, health conditions, and traits. The journey of the DTC-GT initiates by a consumer ordering the test through an online channel. The sample collection kit is provided to the consumers. DNA sample such as saliva or oral swab is collected by the consumer and sent back to the organization for the analysis. Consumers get their test results on their online account within 3-5 weeks.

The Food and Drug Administration (FDA) regulates medical devices in the U.S. to ensure their effectiveness and safety for patients and users. The FDA's Center for Devices and Radiological Health (CDRH) oversees regulating these firms. The FDA must approve every company involved in the manufacturing, packaging, labeling, and/or sale of medical devices sold in the U.S. Electrocardiographs are classified into Class II categories of medical devices in the U.S. These systems are considered as medical devices through the Federal Food, Drug and Cosmetic (FD&C) Act. Diagnostic imaging systems are classified under the category of non-501(k)-exempt Class I and Class II medical devices and do not follow the Pre-Marketing Approval (PMA) pathway by U.S. Food and Drug Administration (FDA). In 501(k) pathways, any new diagnostic imaging devices under Class I and Class II should be legally marketed and should have a clear definition of technological characteristics, applications, and indications.

The scope of the research study titled global hemodynamic monitoring devices market is aimed at assessing the market potential of various hemodynamic monitoring devices. The following were the types of approaches in which the global hemodynamic monitoring devices market was estimated and its growth potential for the forecast period was evaluated:

Heparin is an anticoagulant medication and a naturally occurring glycosaminoglycan produced by basophils and mast cells in all mammals. Heparin is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. The report provides market dynamics and trends related to the global heparin market. The study estimates the revenue generated from the sales of heparin products; however, it excludes the heparin products service revenue. The valuations comprise revenue generated from heparin products such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin.

Health insurance covers medical expenses incurred during treatment of any disease, injury, or other mental & physical impairment. It acts as compensation in exchange for a monthly/semi-annual/annual premium or a payroll tax to provide healthcare benefits. The insurer is obliged to cover medical expenses for the policy holder up till the tenure and coverage of the policy. Depending on the policy, the coverage may vary for numerous factors, including diseases, age group, government policies, and others.